PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer

Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers

GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanced head and neck squamous cell carcinoma

Simplifying molecular subtypes of metastatic gastric cancer

Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma

IMspire170: New combination treatment for advanced melanoma

ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma

Checkmate 227: Final analysis for the non small cell lung cancer trial

PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma

KATHERINE trial updates for HER2-positive breast cancer

PARP inhibitors for metastatic breast cancer

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

Lutetium-177 PSMA scanning for prostate cancer

Highlights from ESMO 2019

SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer patients during the dose escalation phase

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer

Blood first assay screening in patients with ALK positive NSCLC

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines

CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma

Optimal timing of radiotherapy following radical prostatectomy

Safety and tolerability of AVB500 in platinum-resistant recurrent ovarian cancer

INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advanced gastrointestinal stromal tumours

Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer

Holistic management of patients with ALK-positive NSCLC

Precision medicine in ALK-positive NSCLC: Results from the BFAST trial

Prostate cancer updates: Advances in precision medicine and PARP inhibitors

Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019

Role of molecular diagnostics in prostate cancer

Key developments in pancreatic cancer from ESMO 2019

Breast cancer highlights from ESMO 2019

Melanoma highlights from ESMO 2019

ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma

IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Comment: Immunotherapy plus chemotherapy in bladder cancer

Comment: PARP inhibitors for advanced prostate cancer

PARP inhibitor olaparib slows progression of advanced prostate cancer

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

Comment: CDK4/6 inhibitors in advanced breast cancer

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer

Comment: Keynote 522 trial

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma

Ovarian highlights from ESMO 2019

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Comment: Immunotherapy combination for advanced NSCLC

More ovarian cancer patients benefit from maintenance combined targeted therapy

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC

Comment: Osimertinib for EGFR-mutation positive NSCLC

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation